{"id":387121,"date":"2020-11-23T16:08:09","date_gmt":"2020-11-23T21:08:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=387121"},"modified":"2020-11-23T16:08:09","modified_gmt":"2020-11-23T21:08:09","slug":"nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/","title":{"rendered":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BELTSVILLE, Md., Nov.  23, 2020  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LCaqSnvs1bq_SppquoecouWE_TJZoLSLhpVHv-mbYTH91YH7aca8zsYJCch10P_R0P1cOC7trGUMa0rT00VXSw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NextCure, Inc.<\/a> (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1<sup>st<\/sup>.<\/p>\n<p>An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NzsZb9VlEYJLKZ8z-puTht7Atk5Z7esQeD-NoAYGYgZfbmqO88Q6m3gUK38ompA3DrVTc2UC9DS7R2TWxghYfQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.nextcure.com<\/a> and archived on the website for 30 days.<\/p>\n<p>\n        <strong>About NextCure, Inc.<\/strong><br \/>\n        <br \/>NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Our initial focus is to bring hope and new treatments to patients who do not respond to current cancer therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nISO1C9VK-BW7BtwxBlAc9emfERTn6kna-HCHQ3PxTGW1JLe6S7pC3XwYAwsyC7GOcPwVKU0Hl6jhi1cIwYQG70PhLBOqPe3sB9KAQeVWyw=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.nextcure.com<\/a><\/p>\n<p>\n        <strong>Cautionary Statement Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>Statements made in this press release that are not historical facts are forward-looking statements. Words such as \u201cexpects,\u201d \u201cbelieves,\u201d \u201cintends,\u201d \u201chope,\u201d \u201cforward\u201d and similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this press release include, among others, statements about NextCure\u2019s plans, objectives and intentions with respect to the discovery of immunomedicine targets and the discovery and development of immunomedicines. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement. Such risks and uncertainties include, among others: our limited operating history and no products approved for commercial sale; our history of significant losses; our need to obtain additional financing; risks related to clinical development, marketing approval and commercialization; and the unproven approach to the discovery and development of product candidates based on our FIND-IO platform. More detailed information on these and additional factors that could affect NextCure\u2019s actual results are described in NextCure\u2019s filings with the\u00a0Securities and Exchange Commission\u00a0(the \u201cSEC\u201d), including NextCure\u2019s most recent Form 10-K and subsequent Form 10-Q. You should not place undue reliance on any forward-looking statements. NextCure assumes no obligation to update any forward-looking statements, even if expectations change.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9391d554-0bf7-41d4-83de-3fa83852fdb6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Inquiries\r\nTimothy Mayer, Ph.D.\r\nNextCure, Inc.\r\nChief Operating Officer\r\n(240) 762-6486\r\nIR@nextcure.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st. An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company\u2019s website at www.nextcure.com and archived on the website for 30 days. About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-387121","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st. An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company\u2019s website at www.nextcure.com and archived on the website for 30 days. About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand &hellip; Continue reading &quot;NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T21:08:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference\",\"datePublished\":\"2020-11-23T21:08:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/\"},\"wordCount\":398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/\",\"name\":\"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\",\"datePublished\":\"2020-11-23T21:08:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk","og_description":"BELTSVILLE, Md., Nov. 23, 2020 (GLOBE NEWSWIRE) &#8212; NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference on December 1st. An audio webcast of the pre-recorded fireside chat will be available through the Investors section of the company\u2019s website at www.nextcure.com and archived on the website for 30 days. About NextCure, Inc. NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary FIND-IO\u2122 platform, we study various immune cells to discover and understand &hellip; Continue reading \"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T21:08:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference","datePublished":"2020-11-23T21:08:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/"},"wordCount":398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/","name":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=","datePublished":"2020-11-23T21:08:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5MDg5NCMzODQwMzgzIzIxMjU4MzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nextcure-to-present-at-piper-sandler-virtual-32nd-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"NextCure to Present at Piper Sandler Virtual 32nd Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=387121"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/387121\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=387121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=387121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=387121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}